Histogenics Corp. received a notice from Nasdaq for failing to meet the exchange's $1 minimum bid price listing requirement.

The Waltham, Mass.-based biotechnology company has until April 15, 2019, to regain compliance for continued listing on the Nasdaq Capital Market.

If the company fails to regain compliance by then, it may be delisted from the stock exchange.

Histogenics is a clinical-stage company that develops restorative cell therapies in the U.S.